Syschem India FY25-26: Revenue scales to ₹655 Cr as volumes ramp

The presentation states the company is engaged in manufacturing of bulk drugs and intermediates and also undertakes contract manufacturing.

The deck lists Amoxicillin T/H, Ampicillin T/H, Flucloxacillin Sodium, Cloxacillin Sodium, Cephalexin, and Cephadroxil as key products.

The presentation reports FY25-26 revenue of 65,464.70 lakhs, EBITDA of 2,111.38 lakhs, and PAT of 1,093 lakhs.

The deck reports FY25-26 domestic sales of 45,622 lakhs and export sales of 19,839 lakhs. It also notes FY25-26 figures are stated with GST and excise.

The deck reports production of 3,039 MT in FY25-26 versus 1,280 MT in FY24-25, and shows quarterly FY25-26 production rising from 463 MT in Q1 to 1,239 MT in Q4.

The presentation mentions development of dedicated Amoxicillin and related products plants, backward integration to expand existing facilities, workforce growth, and a focus on achieving WHO-GMP certification.

As of 31 March 2026, the deck reports promoter and promoter group shareholding of 60.86% and public shareholding of 39.14%.